Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tocilizumab + albumin-bound paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination therapy consisting of tocilizumab (an IL-6 receptor antagonist), albumin-bound paclitaxel (a cytotoxic antimicrotubule agent), and cisplatin (a platinum-based chemotherapy agent). The combination may potentially target both inflammatory pathways and cancer cells. Tocilizumab blocks IL-6 signaling which may play a role in tumorigenesis, while albumin-bound paclitaxel promotes microtubule assembly and prevents depolymerization, inhibiting cell division. Cisplatin works by crosslinking DNA, preventing cell division and leading to apoptosis.
- Other names
- tirilizumab + albumin-bound paclitaxel + cisplatin
02
Targets
DNAMicrotubuleIL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on tocilizumab + albumin-bound paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tocilizumab + albumin-bound paclitaxel + cisplatin.